Multiple Sclerosis Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2017 to 2021 and Forecast 2022 to 2028

$ PRICE - $ 3,000.00$ 8,900.00

Multiple Sclerosis Market: Disease Type (Clinically Isolated Syndrome (CIS), Relapsing-Remitting MS (RRMS), Secondary Progressive MS (SPMS), Primary Progressive MS (PPMS), Treatment (Medications, Physical Therapy, Plasma Exchange, Stem Cell Therapy), Drug Class (Corticosteroids, Immunomodulators, Sphingosine l-phosphate receptor modulators, Nrf2 activators, Purine analogs, Humanized Monoclonal Antibody, Muscle relaxants, Adamantanes, Potassium Channel Blockers, Immunosuppressants, Interferons, Others), Diagnosis (Magnetic Resonance Imaging, Simple Electrical Stimulation Tests, Lumbar Puncture, Route of Administration (Oral, Parenteral, Others), and Geography

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail
SKU: N/A Categories: ,

Report

Description

1. Executive Summary
2. Global Multiple Sclerosis Market Introduction
2.1. Global Multiple Sclerosis Market – Taxonomy
2.2. Global Multiple Sclerosis Market –Definitions
2.2.1. Disease Type
2.2.2. Treatment
2.2.3. Drug Class
2.2.4. Diagnosis
2.2.5. Route of Administration
2.2.6. Region
3. Global Multiple Sclerosis Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Multiple Sclerosis Market Dynamic Factors – Impact Analysis
3.6. Global Multiple Sclerosis Market – Competition Landscape
4. Global Multiple Sclerosis Market Analysis,2017 – 2021 – and Forecast, 2022 2028
4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. Global Multiple Sclerosis Market, By Disease Type, 2017–2021 and Forecast, 2022–2028 (Revenue, USD Mn)
5.1. Clinically Isolated Syndrome (CIS)
5.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Relapsing-Remitting MS (RRMS)
5.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Secondary Progressive MS (SPMS)
5.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Primary Progressive MS (PPMS)
5.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
6. Global Multiple Sclerosis Market, By Treatment, 2017 – 2021 and Forecast, 2021 – 2027 (Revenue, USD Mn)
6.1. Medications
6.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Physical Therapy
6.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Plasma Exchange
6.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
6.4. Stem Cell Therapy
6.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.4.3. Market Opportunity Analysis
7. Global Multiple Sclerosis Market Forecast, By Drug Class, 2017–2021and Forecast, 2022–2028 (Revenue, USD Mn)
7.1. Corticosteroids
7.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Immunomodulators
7.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Sphingosine l-phosphate receptor modulators
7.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
7.4. Nrf2 activators
7.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3. Market Opportunity Analysis
7.5. Purine analogs
7.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.5.3. Market Opportunity Analysis
7.6. Humanized Monoclonal Antibody
7.6.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.6.3. Market Opportunity Analysis
7.7. Muscle relaxants
7.7.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.7.3. Market Opportunity Analysis
7.8. Adamantanes
7.8.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.8.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.8.3. Market Opportunity Analysis
7.9. Potassium Channel Blockers
7.9.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.9.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.9.3. Market Opportunity Analysis
7.10. Immunosuppressants
7.10.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.10.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.10.3. Market Opportunity Analysis
7.11. Interferons
7.11.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.11.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.11.3. Market Opportunity Analysis
7.12. Others
7.12.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.12.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.12.3. Market Opportunity Analysis
8. Global Multiple Sclerosis Market Forecast, By Diagnosis, 2017 – 2021 and Forecast, 2021 – 2027 (Revenue, USD Mn)
8.1. Magnetic Resonance Imaging
8.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Simple Electrical Stimulation Tests
8.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Lumbar Puncture
8.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
9. Global Multiple Sclerosis Market, By Route of Administration, 2017 – 2021 and Forecast, 2021 – 2027 (Revenue, USD Mn)
9.1. Oral
9.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.1.3. Market Opportunity Analysis
9.2. Parenteral
9.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.2.3. Market Opportunity Analysis
9.3. Others
9.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.3.3. Market Opportunity Analysis
10. Global Multiple Sclerosis Market Forecast, By Region, 2017–2021and Forecast, 2022–2028(Revenue, USD Mn)
10.1. North America
10.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
10.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
10.1.3. Market Opportunity Analysis
10.2. Europe
10.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
10.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
10.2.3. Market Opportunity Analysis
10.3. Asia-Pacific
10.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
10.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
10.3.3. Market Opportunity Analysis
10.4. Latin America
10.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
10.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
10.4.3. Market Opportunity Analysis
10.5. Middle East and Africa
10.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
10.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
10.5.3. Market Opportunity Analysis
10.6. Global Multiple Sclerosis Market – Opportunity Analysis Index, By Treatment, Drug Class, Disease Type, Diagnosis, Route of Administration and Region, 2022 – 2028
11. North America Multiple Sclerosis MarketAnalysis,2017–2021and Forecast, 2022–2028(Revenue, USD Mn)
11.1. Disease Type Analysis 2017–2021and Forecast 2022 – 2028by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
11.1.1. Clinically Isolated Syndrome (CIS)
11.1.2. Relapsing-Remitting MS (RRMS)
11.1.3. Secondary Progressive MS (SPMS)
11.1.4. Primary Progressive MS (PPMS)
11.2. Treatment Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.2.1. Medications
11.2.2. Physical Therapy
11.2.3. Plasma Exchange
11.2.4. Stem Cell Therapy
11.3. Drug Class Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.3.1. Corticosteroids
11.3.2. Immnumomodulators
11.3.3. Sphingosine l-phosphate receptor modulators
11.3.4. Nrf2 activators
11.3.5. Purine analogs
11.3.6. Humanized Monoclonal Antibody
11.3.7. Muscle relaxants
11.3.8. Adamantanes
11.3.9. Potassium Channel Blockers
11.3.10. Immunosuppresents
11.3.11. Interferons
11.3.12. Others
11.4. Diagnosis Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.4.1. Magnetic Resonance Imaging
11.4.2. Simple Electrical Stimulation Tests
11.4.3. Lumbar Puncture
11.4.4. others
11.5. Route of Administration Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.5.1. Oral
11.5.2. Parenteral
11.5.3. Others
11.6. Country Analysis 2017 – 2021 and Forecast 2022 – 2028by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
11.6.1. USA
11.6.2. Canada
11.7. North America Multiple Sclerosis Market – Opportunity Analysis Index, By Treatment, Drug Class, Disease Type, Diagnosis, Route of Administration and Country, 2022 – 2028
11.8. North America Multiple Sclerosis Market Dynamics – Trends
12. Europe Multiple Sclerosis Market Analysis, 2017–2021and Forecast, 2022–2028(Revenue, USD Mn)
12.1. Disease Type Analysis 2017–2021and Forecast 2022 – 2028by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
12.1.1. Clinically Isolated Syndrome (CIS)
12.1.2. Relapsing-Remitting MS (RRMS)
12.1.3. Secondary Progressive MS (SPMS)
12.1.4. Primary Progressive MS (PPMS)
12.2. Treatment Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.2.1. Medications
12.2.2. Physical Therapy
12.2.3. Plasma Exchange
12.2.4. Stem Cell Therapy
12.3. Drug Class Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.3.1. Corticosteroids
12.3.2. Immnumomodulators
12.3.3. Sphingosine l-phosphate receptor modulators
12.3.4. Nrf2 activators
12.3.5. Purine analogs
12.3.6. Humanized Monoclonal Antibody
12.3.7. Muscle relaxants
12.3.8. Adamantanes
12.3.9. Potassium Channel Blockers
12.3.10. Immunosuppresents
12.3.11. Interferons
12.3.12. Others
12.4. Diagnosis Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.4.1. Magnetic Resonance Imaging
12.4.2. Simple Electrical Stimulation Tests
12.4.3. Lumbar Puncture
12.4.4. others
12.5. Route of Administration Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.5.1. Oral
12.5.2. Parenteral
12.5.3. Others
12.6. Country Analysis 2017–2021and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
12.6.1. Germany
12.6.2. UK
12.6.3. France
12.6.4. Spain
12.6.5. Italy
12.6.6. Russia
12.6.7. Poland
12.6.8. Rest of Europe
12.7. Europe Multiple Sclerosis Market – Opportunity Analysis Index, By Treatment, Drug Class, Disease Type, Diagnosis, Route of Administrationand Country, 2022 – 2028
12.8. Europe Multiple Sclerosis Market Dynamics – Trends
13. Asia-Pacific Multiple Sclerosis Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
13.1. Disease Type Analysis 2017–2021and Forecast 2022 – 2028by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
13.1.1. Clinically Isolated Syndrome (CIS)
13.1.2. Relapsing-Remitting MS (RRMS)
13.1.3. Secondary Progressive MS (SPMS)
13.1.4. Primary Progressive MS (PPMS)
13.2. Treatment Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.2.1. Medications
13.2.2. Physical Therapy
13.2.3. Plasma Exchange
13.2.4. Stem Cell Therapy
13.3. Drug Class Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.3.1. Corticosteroids
13.3.2. Immnumomodulators
13.3.3. Sphingosine l-phosphate receptor modulators
13.3.4. Nrf2 activators
13.3.5. Purine analogs
13.3.6. Humanized Monoclonal Antibody
13.3.7. Muscle relaxants
13.3.8. Adamantanes
13.3.9. Potassium Channel Blockers
13.3.10. Immunosuppresents
13.3.11. Interferons
13.3.12. Others
13.4. Diagnosis Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.4.1. Magnetic Resonance Imaging
13.4.2. Simple Electrical Stimulation Tests
13.4.3. Lumbar Puncture
13.4.4. others
13.5. Route of Administration Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.5.1. Oral
13.5.2. Parenteral
13.5.3. Others
13.6. Country Analysis2017–2021and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
13.6.1. Japan
13.6.2. China
13.6.3. India
13.6.4. ASEAN
13.6.5. Australia & New Zealand
13.6.6. Rest of Asia-Pacific
13.7. Asia-Pacific Multiple Sclerosis Market – Opportunity Analysis Index, By Treatment, Drug Class, Disease Type, Diagnosis, Route of Administration and Country,2022 – 2028
13.8. Asia-Pacific Multiple Sclerosis Market Dynamics – Trends
14. Latin America Multiple Sclerosis Market Analysis,2017 – 2021 and Forecast, 2022–2028(Revenue, USD Mn)
14.1. Disease Type Analysis 2017–2021and Forecast 2022 – 2028by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
14.1.1. Clinically Isolated Syndrome (CIS)
14.1.2. Relapsing-Remitting MS (RRMS)
14.1.3. Secondary Progressive MS (SPMS)
14.1.4. Primary Progressive MS (PPMS)
14.2. Treatment Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.2.1. Medications
14.2.2. Physical Therapy
14.2.3. Plasma Exchange
14.2.4. Stem Cell Therapy
14.3. Drug Class Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.3.1. Corticosteroids
14.3.2. Immnumomodulators
14.3.3. Sphingosine l-phosphate receptor modulators
14.3.4. Nrf2 activators
14.3.5. Purine analogs
14.3.6. Humanized Monoclonal Antibody
14.3.7. Muscle relaxants
14.3.8. Adamantanes
14.3.9. Potassium Channel Blockers
14.3.10. Immunosuppresents
14.3.11. Interferons
14.3.12. Others
14.4. Diagnosis Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.4.1. Magnetic Resonance Imaging
14.4.2. Simple Electrical Stimulation Tests
14.4.3. Lumbar Puncture
14.4.4. others
14.5. Route of Administration Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.5.1. Oral
14.5.2. Parenteral
14.5.3. Others
14.6. Country Analysis 2017–2021and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Argentina
14.6.4. Rest of Latin America
14.7. Latin America Multiple Sclerosis Market – Opportunity Analysis Index, By Treatment, Drug Class, Disease Type, Diagnosis, Route of Administration and Country, 2022 – 2028
14.8. Latin America Multiple Sclerosis Market Dynamics – Trends
15. Middle East and Africa Multiple Sclerosis Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
15.1. Disease Type Analysis 2017–2021and Forecast 2022 – 2028by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
15.1.1. Clinically Isolated Syndrome (CIS)
15.1.2. Relapsing-Remitting MS (RRMS)
15.1.3. Secondary Progressive MS (SPMS)
15.1.4. Primary Progressive MS (PPMS)
15.2. Treatment Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
15.2.1. Medications
15.2.2. Physical Therapy
15.2.3. Plasma Exchange
15.2.4. Stem Cell Therapy
15.3. Drug Class Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
15.3.1. Corticosteroids
15.3.2. Immnumomodulators
15.3.3. Sphingosine l-phosphate receptor modulators
15.3.4. Nrf2 activators
15.3.5. Purine analogs
15.3.6. Humanized Monoclonal Antibody
15.3.7. Muscle relaxants
15.3.8. Adamantanes
15.3.9. Potassium Channel Blockers
15.3.10. Immunosuppresents
15.3.11. Interferons
15.3.12. Others
15.4. Diagnosis Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
15.4.1. Magnetic Resonance Imaging
15.4.2. Simple Electrical Stimulation Tests
15.4.3. Lumbar Puncture
15.4.4. others
15.5. Route of Administration Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
15.5.1. Oral
15.5.2. Parenteral
15.5.3. Others
15.6. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
15.6.1. Gulf Cooperation Council (GCC) Countries
15.6.2. Israel
15.6.3. South Africa
15.6.4. Rest of MEA
15.7. MEA Multiple Sclerosis Market – Opportunity Analysis Index, By Treatment, Drug Class, Disease Type, Diagnosis, Route of Administration and Country, 2022 – 2028
15.8. MEA Multiple Sclerosis Market Dynamics – Trends
16. Competition Landscape 
16.1. Strategic Dashboard of Top Market Players
16.2. Company Profiles (Introduction, Financial Analysis, Treatment& Service Drug Class, Key Developments, Strategies, and SWOT Analysis)
16.2.1. F. Hoffmann-La Roche Ltd.
16.2.2. Mylan N.V.
16.2.3. Teva Pharmaceutical Industries Ltd.
16.2.4. Sanofi
16.2.5. Pfizer Inc.
16.2.6. GlaxoSmithKline plc
16.2.7. Novartis AG
16.2.8. Bayer AG
16.2.9. Eli Lilly and Company
16.2.10. Merck & Co., Inc.
16.2.11. Allergan
16.2.12. AstraZeneca
16.2.13. Johnson & Johnson Private Limited
16.2.14. Cipla Inc.
16.2.15. Abbott
16.2.16. AbbVie Inc.
16.2.17. Merck KGaA
16.2.18. Actelion Pharmaceuticals Ltd
16.2.19. Opexa Therapeutics, Inc.
16.2.20. Bayer AG
17. Research Methodology
18. Key Assumptions and Acronyms

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.


Report

Company Profile

 

  • Hoffmann-La Roche Ltd.
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Novartis AG
  • Bayer AG
  • Eli Lilly and Company
  • Merck & Co., Inc.
  • Allergan
  • AstraZeneca
  • Johnson & Johnson Private Limited
  • Cipla Inc.
  • Abbott
  • AbbVie Inc.
  • Merck KGaA
  • Actelion Pharmaceuticals Ltd
  • Opexa Therapeutics, Inc.
  • Bayer AG

Description

1. Executive Summary
2. Global Multiple Sclerosis Market Introduction
2.1. Global Multiple Sclerosis Market – Taxonomy
2.2. Global Multiple Sclerosis Market –Definitions
2.2.1. Disease Type
2.2.2. Treatment
2.2.3. Drug Class
2.2.4. Diagnosis
2.2.5. Route of Administration
2.2.6. Region
3. Global Multiple Sclerosis Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Multiple Sclerosis Market Dynamic Factors – Impact Analysis
3.6. Global Multiple Sclerosis Market – Competition Landscape
4. Global Multiple Sclerosis Market Analysis,2017 – 2021 – and Forecast, 2022 2028
4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. Global Multiple Sclerosis Market, By Disease Type, 2017–2021 and Forecast, 2022–2028 (Revenue, USD Mn)
5.1. Clinically Isolated Syndrome (CIS)
5.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Relapsing-Remitting MS (RRMS)
5.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Secondary Progressive MS (SPMS)
5.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Primary Progressive MS (PPMS)
5.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
6. Global Multiple Sclerosis Market, By Treatment, 2017 – 2021 and Forecast, 2021 – 2027 (Revenue, USD Mn)
6.1. Medications
6.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Physical Therapy
6.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Plasma Exchange
6.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
6.4. Stem Cell Therapy
6.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.4.3. Market Opportunity Analysis
7. Global Multiple Sclerosis Market Forecast, By Drug Class, 2017–2021and Forecast, 2022–2028 (Revenue, USD Mn)
7.1. Corticosteroids
7.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Immunomodulators
7.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Sphingosine l-phosphate receptor modulators
7.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
7.4. Nrf2 activators
7.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3. Market Opportunity Analysis
7.5. Purine analogs
7.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.5.3. Market Opportunity Analysis
7.6. Humanized Monoclonal Antibody
7.6.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.6.3. Market Opportunity Analysis
7.7. Muscle relaxants
7.7.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.7.3. Market Opportunity Analysis
7.8. Adamantanes
7.8.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.8.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.8.3. Market Opportunity Analysis
7.9. Potassium Channel Blockers
7.9.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.9.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.9.3. Market Opportunity Analysis
7.10. Immunosuppressants
7.10.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.10.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.10.3. Market Opportunity Analysis
7.11. Interferons
7.11.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.11.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.11.3. Market Opportunity Analysis
7.12. Others
7.12.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.12.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.12.3. Market Opportunity Analysis
8. Global Multiple Sclerosis Market Forecast, By Diagnosis, 2017 – 2021 and Forecast, 2021 – 2027 (Revenue, USD Mn)
8.1. Magnetic Resonance Imaging
8.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Simple Electrical Stimulation Tests
8.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Lumbar Puncture
8.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
9. Global Multiple Sclerosis Market, By Route of Administration, 2017 – 2021 and Forecast, 2021 – 2027 (Revenue, USD Mn)
9.1. Oral
9.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.1.3. Market Opportunity Analysis
9.2. Parenteral
9.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.2.3. Market Opportunity Analysis
9.3. Others
9.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.3.3. Market Opportunity Analysis
10. Global Multiple Sclerosis Market Forecast, By Region, 2017–2021and Forecast, 2022–2028(Revenue, USD Mn)
10.1. North America
10.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
10.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
10.1.3. Market Opportunity Analysis
10.2. Europe
10.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
10.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
10.2.3. Market Opportunity Analysis
10.3. Asia-Pacific
10.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
10.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
10.3.3. Market Opportunity Analysis
10.4. Latin America
10.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
10.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
10.4.3. Market Opportunity Analysis
10.5. Middle East and Africa
10.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
10.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
10.5.3. Market Opportunity Analysis
10.6. Global Multiple Sclerosis Market – Opportunity Analysis Index, By Treatment, Drug Class, Disease Type, Diagnosis, Route of Administration and Region, 2022 – 2028
11. North America Multiple Sclerosis MarketAnalysis,2017–2021and Forecast, 2022–2028(Revenue, USD Mn)
11.1. Disease Type Analysis 2017–2021and Forecast 2022 – 2028by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
11.1.1. Clinically Isolated Syndrome (CIS)
11.1.2. Relapsing-Remitting MS (RRMS)
11.1.3. Secondary Progressive MS (SPMS)
11.1.4. Primary Progressive MS (PPMS)
11.2. Treatment Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.2.1. Medications
11.2.2. Physical Therapy
11.2.3. Plasma Exchange
11.2.4. Stem Cell Therapy
11.3. Drug Class Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.3.1. Corticosteroids
11.3.2. Immnumomodulators
11.3.3. Sphingosine l-phosphate receptor modulators
11.3.4. Nrf2 activators
11.3.5. Purine analogs
11.3.6. Humanized Monoclonal Antibody
11.3.7. Muscle relaxants
11.3.8. Adamantanes
11.3.9. Potassium Channel Blockers
11.3.10. Immunosuppresents
11.3.11. Interferons
11.3.12. Others
11.4. Diagnosis Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.4.1. Magnetic Resonance Imaging
11.4.2. Simple Electrical Stimulation Tests
11.4.3. Lumbar Puncture
11.4.4. others
11.5. Route of Administration Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.5.1. Oral
11.5.2. Parenteral
11.5.3. Others
11.6. Country Analysis 2017 – 2021 and Forecast 2022 – 2028by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
11.6.1. USA
11.6.2. Canada
11.7. North America Multiple Sclerosis Market – Opportunity Analysis Index, By Treatment, Drug Class, Disease Type, Diagnosis, Route of Administration and Country, 2022 – 2028
11.8. North America Multiple Sclerosis Market Dynamics – Trends
12. Europe Multiple Sclerosis Market Analysis, 2017–2021and Forecast, 2022–2028(Revenue, USD Mn)
12.1. Disease Type Analysis 2017–2021and Forecast 2022 – 2028by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
12.1.1. Clinically Isolated Syndrome (CIS)
12.1.2. Relapsing-Remitting MS (RRMS)
12.1.3. Secondary Progressive MS (SPMS)
12.1.4. Primary Progressive MS (PPMS)
12.2. Treatment Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.2.1. Medications
12.2.2. Physical Therapy
12.2.3. Plasma Exchange
12.2.4. Stem Cell Therapy
12.3. Drug Class Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.3.1. Corticosteroids
12.3.2. Immnumomodulators
12.3.3. Sphingosine l-phosphate receptor modulators
12.3.4. Nrf2 activators
12.3.5. Purine analogs
12.3.6. Humanized Monoclonal Antibody
12.3.7. Muscle relaxants
12.3.8. Adamantanes
12.3.9. Potassium Channel Blockers
12.3.10. Immunosuppresents
12.3.11. Interferons
12.3.12. Others
12.4. Diagnosis Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.4.1. Magnetic Resonance Imaging
12.4.2. Simple Electrical Stimulation Tests
12.4.3. Lumbar Puncture
12.4.4. others
12.5. Route of Administration Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.5.1. Oral
12.5.2. Parenteral
12.5.3. Others
12.6. Country Analysis 2017–2021and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
12.6.1. Germany
12.6.2. UK
12.6.3. France
12.6.4. Spain
12.6.5. Italy
12.6.6. Russia
12.6.7. Poland
12.6.8. Rest of Europe
12.7. Europe Multiple Sclerosis Market – Opportunity Analysis Index, By Treatment, Drug Class, Disease Type, Diagnosis, Route of Administrationand Country, 2022 – 2028
12.8. Europe Multiple Sclerosis Market Dynamics – Trends
13. Asia-Pacific Multiple Sclerosis Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
13.1. Disease Type Analysis 2017–2021and Forecast 2022 – 2028by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
13.1.1. Clinically Isolated Syndrome (CIS)
13.1.2. Relapsing-Remitting MS (RRMS)
13.1.3. Secondary Progressive MS (SPMS)
13.1.4. Primary Progressive MS (PPMS)
13.2. Treatment Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.2.1. Medications
13.2.2. Physical Therapy
13.2.3. Plasma Exchange
13.2.4. Stem Cell Therapy
13.3. Drug Class Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.3.1. Corticosteroids
13.3.2. Immnumomodulators
13.3.3. Sphingosine l-phosphate receptor modulators
13.3.4. Nrf2 activators
13.3.5. Purine analogs
13.3.6. Humanized Monoclonal Antibody
13.3.7. Muscle relaxants
13.3.8. Adamantanes
13.3.9. Potassium Channel Blockers
13.3.10. Immunosuppresents
13.3.11. Interferons
13.3.12. Others
13.4. Diagnosis Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.4.1. Magnetic Resonance Imaging
13.4.2. Simple Electrical Stimulation Tests
13.4.3. Lumbar Puncture
13.4.4. others
13.5. Route of Administration Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.5.1. Oral
13.5.2. Parenteral
13.5.3. Others
13.6. Country Analysis2017–2021and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
13.6.1. Japan
13.6.2. China
13.6.3. India
13.6.4. ASEAN
13.6.5. Australia & New Zealand
13.6.6. Rest of Asia-Pacific
13.7. Asia-Pacific Multiple Sclerosis Market – Opportunity Analysis Index, By Treatment, Drug Class, Disease Type, Diagnosis, Route of Administration and Country,2022 – 2028
13.8. Asia-Pacific Multiple Sclerosis Market Dynamics – Trends
14. Latin America Multiple Sclerosis Market Analysis,2017 – 2021 and Forecast, 2022–2028(Revenue, USD Mn)
14.1. Disease Type Analysis 2017–2021and Forecast 2022 – 2028by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
14.1.1. Clinically Isolated Syndrome (CIS)
14.1.2. Relapsing-Remitting MS (RRMS)
14.1.3. Secondary Progressive MS (SPMS)
14.1.4. Primary Progressive MS (PPMS)
14.2. Treatment Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.2.1. Medications
14.2.2. Physical Therapy
14.2.3. Plasma Exchange
14.2.4. Stem Cell Therapy
14.3. Drug Class Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.3.1. Corticosteroids
14.3.2. Immnumomodulators
14.3.3. Sphingosine l-phosphate receptor modulators
14.3.4. Nrf2 activators
14.3.5. Purine analogs
14.3.6. Humanized Monoclonal Antibody
14.3.7. Muscle relaxants
14.3.8. Adamantanes
14.3.9. Potassium Channel Blockers
14.3.10. Immunosuppresents
14.3.11. Interferons
14.3.12. Others
14.4. Diagnosis Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.4.1. Magnetic Resonance Imaging
14.4.2. Simple Electrical Stimulation Tests
14.4.3. Lumbar Puncture
14.4.4. others
14.5. Route of Administration Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.5.1. Oral
14.5.2. Parenteral
14.5.3. Others
14.6. Country Analysis 2017–2021and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Argentina
14.6.4. Rest of Latin America
14.7. Latin America Multiple Sclerosis Market – Opportunity Analysis Index, By Treatment, Drug Class, Disease Type, Diagnosis, Route of Administration and Country, 2022 – 2028
14.8. Latin America Multiple Sclerosis Market Dynamics – Trends
15. Middle East and Africa Multiple Sclerosis Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
15.1. Disease Type Analysis 2017–2021and Forecast 2022 – 2028by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
15.1.1. Clinically Isolated Syndrome (CIS)
15.1.2. Relapsing-Remitting MS (RRMS)
15.1.3. Secondary Progressive MS (SPMS)
15.1.4. Primary Progressive MS (PPMS)
15.2. Treatment Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
15.2.1. Medications
15.2.2. Physical Therapy
15.2.3. Plasma Exchange
15.2.4. Stem Cell Therapy
15.3. Drug Class Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
15.3.1. Corticosteroids
15.3.2. Immnumomodulators
15.3.3. Sphingosine l-phosphate receptor modulators
15.3.4. Nrf2 activators
15.3.5. Purine analogs
15.3.6. Humanized Monoclonal Antibody
15.3.7. Muscle relaxants
15.3.8. Adamantanes
15.3.9. Potassium Channel Blockers
15.3.10. Immunosuppresents
15.3.11. Interferons
15.3.12. Others
15.4. Diagnosis Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
15.4.1. Magnetic Resonance Imaging
15.4.2. Simple Electrical Stimulation Tests
15.4.3. Lumbar Puncture
15.4.4. others
15.5. Route of Administration Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
15.5.1. Oral
15.5.2. Parenteral
15.5.3. Others
15.6. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
15.6.1. Gulf Cooperation Council (GCC) Countries
15.6.2. Israel
15.6.3. South Africa
15.6.4. Rest of MEA
15.7. MEA Multiple Sclerosis Market – Opportunity Analysis Index, By Treatment, Drug Class, Disease Type, Diagnosis, Route of Administration and Country, 2022 – 2028
15.8. MEA Multiple Sclerosis Market Dynamics – Trends
16. Competition Landscape 
16.1. Strategic Dashboard of Top Market Players
16.2. Company Profiles (Introduction, Financial Analysis, Treatment& Service Drug Class, Key Developments, Strategies, and SWOT Analysis)
16.2.1. F. Hoffmann-La Roche Ltd.
16.2.2. Mylan N.V.
16.2.3. Teva Pharmaceutical Industries Ltd.
16.2.4. Sanofi
16.2.5. Pfizer Inc.
16.2.6. GlaxoSmithKline plc
16.2.7. Novartis AG
16.2.8. Bayer AG
16.2.9. Eli Lilly and Company
16.2.10. Merck & Co., Inc.
16.2.11. Allergan
16.2.12. AstraZeneca
16.2.13. Johnson & Johnson Private Limited
16.2.14. Cipla Inc.
16.2.15. Abbott
16.2.16. AbbVie Inc.
16.2.17. Merck KGaA
16.2.18. Actelion Pharmaceuticals Ltd
16.2.19. Opexa Therapeutics, Inc.
16.2.20. Bayer AG
17. Research Methodology
18. Key Assumptions and Acronyms

ASIA PACIFIC OFFICE

Precision Business Insights, MIG 366, SAI PLAZA, 1st Floor, KPHB Colony, Hyderabad - 500072

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX